Changchun GeneScience Pharmaceutical Co., Ltd, a biopharmaceutical company based in China, has entered into an agency collaboration agreement with Taiwan’s TWi Pharmaceuticals, Inc. for the distribution of the latter’s megestrol in several Asian markets. According to the agreement, the financial details of which were not disclosed, GeneScience will assume the role of the exclusive general agent for the drug in China mainland, Hong Kong, Macau, and Singapore.
Megestrol, indicated for the treatment of anorexia in patients with acquired immunodeficiency syndrome (AIDS) and significant weight loss due to cachexia in patients with AIDS and cancer, received approval from the Chinese regulatory authorities in 2021.- Flcube.com
